Burkina Faso vs Philippines: Average cost of multi drug-resistant tuberculosis treatment
Burkina Faso
159 constant 2022 US$
in 2024
Philippines
310 constant 2022 US$
in 2024
Burkina Faso rank
91st
Philippines rank
89th
Average cost of multi drug-resistant tuberculosis treatment over time
- Burkina Faso
- Philippines
How they compare
Philippines currently reports 310 constant 2022 US$ against 159 constant 2022 US$ in Burkina Faso, a difference of 151 constant 2022 US$.
That makes Philippines's figure about 1.9 times Burkina Faso's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Philippines ahead.
Burkina Faso ranks 91st and Philippines ranks 89th of 92 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burkina Faso | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 304.33 constant 2022 US$ | 4,921 constant 2022 US$ | 4,616 constant 2022 US$ | Philippines |
| 2020s | 741 constant 2022 US$ | 1.36 million constant 2022 US$ | 1.35 million constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burkina Faso or Philippines?
- Philippines, at 310 constant 2022 US$ against 159 constant 2022 US$ in Burkina Faso as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burkina Faso and Philippines?
- 151 constant 2022 US$, with Philippines ahead.
- How many years of comparable data are there for Burkina Faso and Philippines?
- 8 years are reported by both, from 2017 to 2024.
- How do Burkina Faso and Philippines rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burkina Faso ranks 91st and Philippines ranks 89th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.